BioSpace News Archive

Novaremed AG announces the simultaneous publication of data from three Phase 1 studies in Clinical Pharmacology in Drug Development and one Phase 2a, placebo-controlled, dose-finding, proof of concept study in European Journal of Pain with the Company’s lead investigational drug candidate NRD.E1, an innovative non-opioid therapy for painful diabetic peripheral neuropathy.

Olympus, a global technology leader in designing and delivering innovative medical technology solutions, announced today the first commercial treatment of Benign Prostatic Hyperplasia (BPH) in Canada using the minimally invasive iTind™ procedure.

The Company anticipates that the Annual Continuous Disclosure Documents will be filed on or prior to July 29, 2022 and the Interim Continuous Disclosure Documents will be filed shortly thereafter.

ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and the prevention of end-stage renal disease (ESRD) requiring dialysis or transplant, today published data from a patient study confirming the mechanistic action of its lead candidate REACT™ with cell marker analysis.

I-Mab (“I-Mab” or the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it was ranked among the top companies in five different categories by leading global financial publication.

RaySearch Laboratories AB announces the release of the latest version of RayCare®*, the next generation oncology information system.

IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer, today announced the appointment of William G. Kaelin Jr., M.D., to its Board of Directors.

Biotricity Inc. today announced that the Company is expected to join the Russell Microcap Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the US market opens on June 27, 2022.

Viva Biotech 2022 Partnership Summit was successfully held.

Expanded eligibility for patients who have received multiple therapies as first line therapy for GBM.